Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT06725368 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: PCC

Sponsor

Centre Paul Strauss